Shares of Theravance (NASDAQ: THRX), a healthcare royalty management company for a focus on respiratory products, were down big during September after the company and its partner GlaxoSmithKline PLC (GSK -0.83%) released disappointing clinical news.
Are the shares a buy after the fall? See the presentation below for details.
The next billion-dollar iSecret
The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here.
